바이오테크 보도자료
-
- Rhizen Pharmaceuticals AG Presents Data on Its Differentiated PARP and DHODH Inhibitor Programs at AACR 2022
- Rhizen Pharmaceuticals AG (Rhizen), a Switzerland-based privately held, clinical-stage oncology & inflammation-focussed biopharmaceutical company, announced the release of data on its differentiated next-gen...
- 2022년 04월 11일
-
- Alvotech and STADA Pave Way to Launching HUKYNDRA®(AVT02), a Citrate-free, High-concentration Biosimilar to Humira® by Resolving European Patent Dispute With AbbVie
- Alvotech Holdings S.A. (“Alvotech”), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, has today announced the resolution of...
- 2022년 04월 07일
-
- Takeda and the New York Academy of Sciences Announce 2022 Innovators in Science Award Winners
- Takeda (TSE:4502/NYSE:TAK) and the New York Academy of Sciences today announced the winners of the fourth Innovators in Science Award for their excellence in, and commitment to, innovative science that has s...
- 2022년 04월 06일
-
- Saladax Biomedical, Inc. Acquires Intellectual Property Portfolio for Antipsychotic Drug Tests
- Saladax Biomedical, Inc. (Saladax) is pleased to announce that it has acquired a patent portfolio for antipsychotic drug testing from Janssen Pharmaceutica NV. This intellectual property (IP) portfolio inclu...
- 2022년 04월 06일
-
- Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
- In 2021, Boehringer Ingelheim again stepped up its annual investments in R&D to a new high in its 137-year history. The company spent 4.1 billion EUR on R&D (2020: 3.7 billion EUR), up 11.7%. R&D investments...
- 2022년 04월 05일
-
- DIAMOND trial: Veltassa® enables patients to achieve long-term potassium control and optimized RAASi therapy
- Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma today announced full results from its phase-IIIb DIAMOND trial showing that Veltassa® allowed patients to achieve long-term potassium ...
- 2022년 04월 04일
-
- Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
- Takeda (TOKYO:4502/NYSE:TAK) today announced that its Board of Directors will propose two new candidates for independent external directors at the 146th Ordinary Meeting of Shareholders on June 29, 2022. The...
- 2022년 04월 04일
-
- Merck Shares Advances in MS Portfolio with Key Efficacy and Safety Data at AAN 2022
- DARMSTADT, Germany--(BUSINESS WIRE)-- Merck, a leading science and technology company, today announced 13 abstracts from the Company’s multiple sclerosis (MS) portfolio will be presented at the 2022 American...
- 2022년 04월 04일
-
- Labcorp Renews Strategic Partnership with Medidata to Provide Suite of Clinical Trial Technologies and Services
- Medidata, a Dassault Systèmes company, announced that Labcorp, a leading global life sciences company, has selected Medidata's technology platform to extend their 14-year partnership, the foundation of their...
- 2022년 04월 01일
-
- Waters Introduces Xevo TQ Absolute - The Most Sensitive and Compact Benchtop Tandem Quadrupole Mass Spectrometer
- Waters Corporation (NYSE:WAT) today introduced the new Xevo™ TQ Absolute system, the most sensitive and compact benchtop tandem mass spec in its class.[i] Waters’ newest high-performance mass spectrometer is...
- 2022년 04월 01일
-
- Yokogawa Successfully Completes Proof of Concept for Optimization of Operations at US Wastewater Reclamation Facility Producing Potable Water
- Yokogawa Electric Corporation (TOKYO: 6841) announces that it has successfully completed a proof of concept test of technology that reduces energy consumption and stabilizes the quality of the water discharg...
- 2022년 03월 31일
전시회
